MindBio Therapeutics Corp. has appointed Felipe Leyton to lead the commercialization of its AI-powered voice analytics platform for drug and alcohol impairment detection across South America's mining industry. Leyton, a prominent figure in drug and alcohol policy and mining safety, played a central role in implementing Chile's Zero Tolerance framework for alcohol-impaired driving and will now spearhead the deployment of MindBio's technology in one of the world's largest industrial markets.
The appointment marks a strategic shift for MindBio from development to commercial field deployment. Leyton's background includes serving as Head of Chile's National Alcohol Prevention Unit and Head of National Prevention Programs, where he expanded roadside control coverage and enforcement capacity. He also contributed to the design of Chile's national roadside drug testing program launched in 2019. Currently a Partner at TConsulting, he advises major mining operators, government ministries, and international organizations on prevention strategy, regulatory compliance, and safety culture transformation.
Leyton's mandate with MindBio involves developing mining-specific testing protocols, expanding clinical validation, refining AI prediction models, strengthening multi-substance detection for cocaine, benzodiazepines, amphetamines, cannabis, hallucinogens, and alcohol, and creating scalable enterprise licensing frameworks. His direct mining industry engagement and regulatory expertise are expected to accelerate enterprise adoption and revenue generation in the region.
MindBio is nearing completion of a prototype Edge AI hardware-software kiosk system designed for industrial environments, with on-site field testing at mining operations scheduled to begin in Q2 2026. The platform offers rapid, non-invasive screening using voice analysis for real-time impairment prediction, scalable on-site deployment, and reduced operational friction compared to traditional biological testing methods.
The South American mining sector presents a substantial safety market opportunity. In Chile alone, alcohol consumption among mining workers exceeds 75%, with approximately 40% classified as problem drinkers and 9% reporting drug use, within a workforce of over 200,000 individuals. Globally, an estimated 20–25% of occupational accidents are linked to substance use, highlighting the need for real-time impairment detection technologies in safety-critical industries.
Justin Hanka, CEO of MindBio, stated that Leyton's credibility and access position the company at the forefront of next-generation industrial safety solutions. MindBio continues to develop scalable, non-invasive technologies aimed at improving safety outcomes, reducing liability exposure, and modernizing impairment detection across high-risk industries worldwide. For more information, visit www.mindbiotherapeutics.com.
